Novartis increases sales of Genmab-developed sclerosis drug

On Wednesday, Novartis presented its full-year financial report, including sales figures for sclerosis drug Kesimpta, which was originally developed in Genmab’s labs.
Photo: CHARLES PLATIAU/Reuters / X00217
Photo: CHARLES PLATIAU/Reuters / X00217
by marketwire, translated by daniel pedersen

Genmab’s Swiss partner, Novartis, continues to push sales for sclerosis drug Kesimpta.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading